Cipla received USFDA approval for Albendazole

Mumbai: Cipla Limited announced that it has received final approval for its abbreviated new drug application (ANDA) for Albendazole Tablets 200 mg from the United States Food and Drug Administration (USFDA).

Cipla’s Albendazole Tablets 200 mg is an AB-rated generic therapeutic equivalent version of Impax Laboratories, Inc.’s, Albenza.

It is an anthelmintic drug indicated for use in Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

According to IQVIA (IMS Health), Albenza had US sales of approximately USD 99 million for the 12-month period ending July 2018.